Trial Profile
TRC Autologous Bone Marrow Cells for the Treatment of Appendicular Skeletal Fracture Non-Union
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 15 Mar 2017
Price :
$35
*
At a glance
- Drugs Ixmyelocel-T (Primary)
- Indications Fracture
- Focus Therapeutic Use
- Sponsors Vericel Corporation
- 08 Mar 2017 Status changed from completed to discontinued for business reasons (not safety reasons).
- 02 Dec 2014 New trial record